Funding for Faculty

Siteman Funding Opportunities Newsletter

Download the latest Siteman Funding Opportunities Newsletter (PDF) The newsletter and the list of open opportunities on this page are not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed here.

How are we doing? Send us your suggestions! Please let us know how we can improve this page, the newsletter, or anything else related to funding opportunity dissemination. 

Rolling Deadlines: Internal Grant Resources (≤$25K)

SBQSR Grant Support – Siteman Biostatistics and Qualitative Research Shared Resource

Additional Details

RFP Snapshot: The Siteman Biostatistics and Qualitative Research Shared Resource provides advice and support to PIs in preparation of grant applications.

Max Amount and Period: N/A

Eligibility: Must be Siteman Cancer Center members.

Due Date: Rolling

WUSTL CDC Match Grants – WUSTL Center for Drug Discovery

Additional Details

RFP Snapshot: The WUSTL CDC has various match funding programs as follows:

  • CDD Match Grant15
  • CDD Match Grant25

Max Amount and Period: Varies

Eligibility: Varies

Due Date: Rolling

WUSM ICTS Innovation Awards – Institute of Clinical and Translational Sciences

Additional Details

RFP Snapshot: The purpose of these Precision Health Innovation awards is to advance initial discovery pilots for Precision Health ICTS investigators. Proposals are not for developed projects but are to fund developmental or early stage work, including pilot data collection and analysis, in preparation for submission of future external funding.

Max Amount and Period: $25,000 for 1 year

Eligibility: Applicants must be full time faculty at WUSTL or an ICTS partner institution and must be a member of the ICTS.

Due Date: Rolling    

WUSM ICTS Just-in-Time (JIT) Core Usage Funding Program – Institute of Clinical and Translational Sciences and Siteman Cancer Center

Additional Details

RFP Snapshot: The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores (pdf) for research advancing medical knowledge that can improve human health. The Siteman Cancer Center will co-sponsor cancer-focuses proposals.

Max Amount and Period: Varies

Eligibility: Applicant must be a registered member of the ICTS and hold a faculty level appointment at WUSTL or an ICTS partner institution.

Due Date: Rolling

March Deadlines

March 1: LOI: Evidence for Action: Indigenous-Led Solutions to Advance Health Equity and Wellbeing

Additional Details

RFP Snapshot: The purpose of this call for proposals (CFP) is to support Indigenous-led systematic inquiry to enhance the health and well-being of Indigenous Peoples and generate approaches to improve health equity. This will be achieved by funding community-prioritized investigation, elevating and integrating Indigenous cultures and knowledge-building practices. To support a diverse range of projects tailored to different phases of development and scope, awards will be made through two tracks, as described later in this solicitation.

Max Amount and Period: 

Track 1 – Initiating and Developing Research Capacity and Infrastructure: $100,000-$400,000 over 2-3 years (preference). Up to 5 years considered.

Track 2 – Supporting Later-Stage, Sustained Research Efforts: $500,000-$750,000 over 2-3 years (preference). Up to 5 years considered.

Eligibility: Only one organization may serve as the lead applicant.

  • For Track 1, this must be a Tribal entity or Indigenous-Serving Organization.
  • For Track 2, this is not required to be a Tribal entity or Indigenous-Serving Organization. Preference will be given to applicant organizations that are Tribal entities (including those that are state recognized, federally recognized, or have no formal recognition status) or Indigenous-Serving Organizations2, including Urban Indian Organizations.

Due Date: “Brief Proposal” Due: March 1, 2024 at 2PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4: LOI: AACR Gertrude B. Elion Cancer Research Award - American Association for Cancer Research

Additional Details

RFP Snapshot: This is a joint effort between GlaxoSmithKline and AACR to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.

Max Amount and Period: $225,000 for 1 year

Eligibility: Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. They must hold a tenure-eligible position at the rank of Assistant Professor. Applicants cannot be tenured or under consideration for a tenured academic position at the time of application. Applicants must have completed their most recent doctoral degree with the past 11 years. Applicants must also be active AACR members in good standing. Nonmembers can apply for membership online.

Due Date: Letter of Intent Due: March 4, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4 LOI: LCRF Leading Edge Research Grant Program - Lung Cancer Research Foundation

Additional Details

RFP Snapshot: The goal of the 2024 LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process.

Due Date: Letter of Intent Due: March 4, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4 LOI: LCRF Minority Career Development Award (CDA) in Lung Cancer - Lung Cancer Research Foundation

Additional Details

RFP Snapshot: The LCRF Minority Career Development Award (CDA) for Lung Cancer is a two-year career development award intended to support early-stage scientists from underrepresented groups working in lung cancer and working in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research. The objective of this award is to increase the number of highly skilled and trained researchers from groups that are historically underrepresented in academia, medicine, and leadership in lung cancer research.

Max Amount and Period: $150,000 over 2 years

Eligibility: Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research. This includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaskan Natives, Native Hawaiians and other Pacific Islanders. Individuals from racial or ethnic groups that can demonstrate convincingly that they are underrepresented by the host institution will also be eligible. Applicants must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators within 10 years of receiving their MD and/or Ph.D. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics. Exceptions may also be made for those who did training outside the US. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years.

Due Date: Letter of Intent Due: March 4, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4 LOI: LCRF Research Grant on Early-Detection and Pre-Neoplasia in Lung Cancer - Lung Cancer Research Foundation

Additional Details

RFP Snapshot: This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or prevention of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics.

Due Date: Letter of Intent Due: March 4, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4 LOI: LCRF Research Grants on Understanding Resistance in Lung Cancer - Lung Cancer Research Foundation

Additional Details

RFP Snapshot: This grant mechanism will focus on understanding the development, prevention, and therapy of resistance by supporting projects that are identifying, characterizing, treating or preventing resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics.

Due Date: Letter of Intent Due: March 4, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 4 LOI: IASLC/LCRF Team Science Award on Advancing Therapies Towards Curing Oncogene-Driven Lung Cancers

Additional Details

RFP Snapshot: This grant mechanism will focus on furthering the development of novel therapies, including immunotherapeutic approaches, for patients with oncogene-driven lung cancers. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the immediate potential to increase survivorship. Given the specific interest in the development of novel therapies that could benefit this group of patients in the relatively near-term, a clinical trial must either be initially incorporated into the project or be an immediate result of the outcome of the research. It is expected that a program of correlative, translational research will be proposed that will enhance the understanding of these oncogenic-driven lung cancers.

Max Amount and Period: $2.4M over 4 years

Eligibility: Eligible teams must be comprised of independent faculty-level researchers providing complementary interdisciplinary expertise, each of which will make separate but closely integrated contributions to the research being done. One team member should be designated as the Team Leader or Principal Investigator (PI) of the program. This individual will be responsible for the administrative leadership of the project. There should be one Project Leader per project. An individual can serve as both the PI of the proposal and as Project Leader of a project. All project leaders must show clear evidence of an independent research program, be investigators past the initial five years of their first academic appointment and must hold a full-time faculty position at the level of assistant professor or higher. Team members may be working within the same institution or at several institutions. Teams or team members from international sites are highly encouraged. There is no limit on the number of team members. Applicants may only apply for one LCRF grant per cycle. Applicants are prohibited from applying if they are currently receiving funding from IASLC or LCRF.

Due Date: Letter of Intent Due: March 4, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 8: International Research Scientist Development Award (IRSDA) (K01) (Independent Clinical Trial Not Allowed) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries) leading to an independently-funded research career focused on global health. This Notice of Funding Opportunity (NOFO) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors.

Max Amount and Period: $420,000 – $700,000 over 3-5 years

Eligibility: Candidates for this award must have a research or health-professional doctoral degree (including PhD, MD, DO, DC, ND, DDS, DMD, DVM, ScD, DNS, PharmD or equivalent doctoral degrees) received at least two years prior to the application deadline and have research experience beyond their doctoral training. By the time of award, the individual must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status). Current and former PDs/PIs (including Multiple PDs/PIs) on NIH research project (R01), program project (P01), research training (D43), or center (P50) grants, sub-projects of program project (P01) or center (P50) grants, other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or the equivalent to these grants/awards (including non-NIH equivalent grants/awards from other research funding organizations) are not eligible. Current and former PDs/PIs (including Multiple PDs/PIs) of an NIH Small Grant (R03), Exploratory/Developmental Grant (R21/R33), Dissertation Award (R36), or SBIR/STTR (R41, R42, R43, R44) remain eligible. Individuals supported by institutional K awards (K12 or KL2) remain eligible but cannot exceed 6 years of combined institutional K plus individual K01 funding.

Due Date: March 8, 2024 at 5PM CST

March 8: International Research Scientist Development Award (IRSDA) (K01) (Independent Clinical Trial Required) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries) leading to an independently-funded research career focused on global health. This Notice of Funding Opportunity (NOFO) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors.

Max Amount and Period: $420,000 – $700,000 over 3-5 years

Eligibility: Candidates for this award must have a research or health-professional doctoral degree (including PhD, MD, DO, DC, ND, DDS, DMD, DVM, ScD, DNS, PharmD or equivalent doctoral degrees) received at least two years prior to the application deadline and have research experience beyond their doctoral training. By the time of award, the individual must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status). Current and former PDs/PIs (including Multiple PDs/PIs) on NIH research project (R01), program project (P01), research training (D43), or center (P50) grants, sub-projects of program project (P01) or center (P50) grants, other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or the equivalent to these grants/awards (including non-NIH equivalent grants/awards from other research funding organizations) are not eligible. Current and former PDs/PIs (including Multiple PDs/PIs) of an NIH Small Grant (R03), Exploratory/Developmental Grant (R21/R33), Dissertation Award (R36), or SBIR/STTR (R41, R42, R43, R44) remain eligible. Individuals supported by institutional K awards (K12 or KL2) remain eligible but cannot exceed 6 years of combined institutional K plus individual K01 funding.

Due Date: March 8, 2024 at 5PM CST

March 11: Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional) - NIH/NCI

Additional Details

RFP Snapshot: This NOFO supports applications that propose implementation research to reduce the risks of non-communicable diseases in the context of cities in LMICs and/or among AI/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. NIH defines implementation research as the scientific study of the use of strategies to adopt and integrate evidence-based health interventions into clinical and community settings to improve individual outcomes and benefit population health.

Max Amount and Period: No limit over 5 years, but must reflect needs of project

Eligibility: Applications will be accepted from US and LMIC institutions only. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

Due Date: March 11, 2024 at 5PM CST

March 11: LOI: Improving Breast Cancer (BC) Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa - ASCO, Conquer Cancer Foundation and Pfizer

Additional Details

RFP Snapshot: This is a Quality Improvement grant funding opportunity to improve the quality of care and to help build capacity to address the needs of breast cancer (BC) patients in Sub-Saharan Africa. This grant program will support innovative projects to improve the quality of BC patient care in the select geographies in the region

Max Amount and Period: $80,000 over 2 years

Eligibility: PI and focus of submission must be based in Sub-Saharan Africa. Collaborations with institutions outside the region are permitted. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Pathology, Physiotherapy, Psychology, or Social Work. Additional advanced degrees may be considered on a case-by-case basis.

Due Date: Letter of Intent Due: March 11, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 12: LOI: The Mark Foundation Endeavor Awards

Additional Details

RFP Snapshot: The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

Max Amount and Period: $3M over 3 years

Eligibility: Applicants must have an independent faculty research appointment (tenure-track or equivalent) at a non-profit academic institution. There are no citizenship requirements. Applicant teams must be composed of one PI and between 2 and 8 co-PIs. Inter-institutional collaborations are permitted and encouraged. Teams are encouraged to consider diversity in terms of discipline, seniority, gender, race, ethnicity, and any other parameters that will enhance the team’s ability to approach challenging problems from fresh perspectives.

Due Date: Letter of Intent Due: March 12, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 13: The Distinguished Scientist Award in Brain Cancer Research - The Sontag Foundation

Additional Details

RFP Snapshot: This grant supports the scientific careers of young investigators pursing high-risk brain cancer research projects at a critical stage in their research.

Max Amount and Period: $750,000 over 5 years

Eligibility: Applicants must hold a doctoral degree in a discipline with applicability to brain cancer research. Applicants must have received their first independent faculty appointment no earlier than March 1, 2019 and no later than January 1, 2024 at a tax-exempt academic, research, or medical institution within the United States or an equivalent institution in Canada. If the institution grants tenure, the qualifying appointment must be on the tenure track. Applicant’s career track and proposed research should demonstrate outstanding promise as contributors to science relevant to brain cancer research (basic science & related fields encouraged to apply). More than one individual from the institution may apply for this award.

Due Date: March 13, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 14: BCRF Young Investigator Award for Diveristy and Inclusion in Breast Cancer Research - Conquer Cancer, The ASCO Foundation and the Breast Cancer Research Foundation

Additional Details

RFP Snapshot: The Conquer Cancer – Breast Cancer Research Foundation Young Investigator Award (YIA) for Diversity and Inclusion in Breast Cancer Research is designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. The YIA will provide funding to promising investigators who identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment as they seek to build a career in clinical breast cancer research. The YIA is a mentored award, and the research project must be conducted under the guidance of a scientific mentor. Applications are accepted from U.S. and international applicants.

Max Amount and Period: $50,000 for 1 year

Eligibility: Self-identify as a member of a racial and/or ethnic group traditionally excluded in academic medicine according to the AAMC definition (include but are not limited to: American Indian/Alaska Native, Black/African American, Hispanic/Latino, and Native Hawaiian/Other Pacific Islander). Individual demographic information will be requested upon application. Be a physician (MD, DO, or international equivalent) working in any country and currently in the last two years of their final oncology subspecialty training at an academic medical institution and within 10 years of obtaining their medical degree at the time of grant submission. Applicant must also be an ASCO member and be able to commit at least 60% of full-time effort in total research.

Due Date: March 14, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 15: LOI: Siteman Investment Program Research Development Awards (SIP RDA - 2024 Cycle 1) - Siteman Cancer Center

Additional Details

RFP Snapshot: The SIP RDA is designed to award development funding to faculty investigators to support pioneering cancer research and produce data to leverage further external peer-reviewed funding. Available mechanisms include: New and Established Clinical Trials, Phase 0/1 Brain Tumor Center (BTC) Clinical Trials, Pre-R01, Pre-R01 for Collaborations with University of Missouri-Columbia, Team Science, and COE Supplement.

Max Amount and Period: Varies by mechanism from $50,000 to $800,000 over 1-3 years

Eligibility: The PI must have a full-time faculty appointment at Washington University (WU), Saint Louis University (SLU), or the University of Missouri-Columbia (MU). Faculty from Saint Louis University and University of Missouri-Columbia are required to have a WU Siteman Cancer Center faculty member as co-PI. The contact PI submitting the application must be a Siteman Cancer Center member or must submit a membership application by the SIP RDA full application deadline. See RFA for full eligibility guidelines.

Due Date: Letter of Intent Due: March 15, 2024 at 4PM CST

March 15: ASA Sun Pharma Investigative Scientist Award - American Skin Association

Additional Details

RFP Snapshot: This grant is meant to foster the career development of a young investigator working at the level of instructor through associate professor in the field of dermatology or cutaneous biology. The aim of the program is to provide bridge support for young investigators. Special consideration will be given to individuals without significant prior support.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicant must have a strong career goal and be dedicated to breakthroughs within the field of dermatology. The research must be focused on new discoveries in the basic or translational medical sciences. While there is no age limit to apply, preference is given to those under the age of 45 with a rank of Instructor up through Associate Professor. If an MD, the candidate must be Board certified in dermatology with at least three years of in-depth experience in investigative dermatology. If a PhD, the candidate must have at least three years of postdoctoral or faculty-level experience in investigative dermatology. The candidate must be identified as a current or future leader in dermatological investigation, and must spend at least 80% of their professional time in research

Due Date: March 15, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 15: ASA Le Roche-Posay Research Grant - Melanoma and Skin Cancer - American Skin Association

Additional Details

RFP Snapshot: American Skin Association (ASA) is accepting applications for support of research in melanoma and skin cancer.

Max Amount and Period: $15,000 for 1 year

Eligibility: Applicants must be working actively in areas related to dermatology targeting melanoma and skin cancer. Funds may be used for support of a new or ongoing research/clinical investigation project. There is no age requirement. However, applicants without prior funding, who are in a formative stage of their career, or who are undergoing a mid-career research change, will be given preference.

Due Date: March 15, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 18: LOI: NTRF Investigator Award - Neuroendocrine Tumor Research Foundation

Additional Details

RFP Snapshot: These medium-sized grants mist have two (or three smaller) aims that describe work requiring two years to complete.

Max Amount and Period: $270,000 over 2 years

Eligibility: Applicants must have an MD, PhD, MD/PhD and have a faculty appointment or equivalent position (at Assistant Professor or above). Research track faculty are eligible to apply.

Due Date: Letter of Intent Due: March 18, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 18: LOI: NTRF Pilot Award - Neuroendocrine Tumor Research Foundation

Additional Details

RFP Snapshot: These pilot awards fund pilot or feasibility studies with one (or two smaller) aims that describe work requiring one year to complete.

Max Amount and Period: $90,000 for 1 year

Eligibility: Applicants must have an MD, PhD, MD/PhD and have a faculty appointment or equivalent position (at Assistant Professor or above). Research track faculty are eligible to apply.

Due Date: Letter of Intent Due: March 18, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 18: SITC-MRA Women in Melanoma Fellowship Award - Society for Immunotherapy of Cancer, Melanoma Research Alliance

Additional Details

RFP Snapshot: SITC-MRA Women in Melanoma Fellowship Award supports a women who has an MD, PhD, or MD/PhD degree with a vested interest in furthering research in cancer immunotherapy for the treatment of patients with melanoma.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must be at the rank of Assistant Professor, be within four years of acquiring the first full-time faculty appointment, have a pre-arranged fellowship mentor, and be a current SITC member in good standing. Domestic and international applicants are welcome to apply.

Due Date: March 18, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 19: Harold Amos Medical Faculty Development Program (AMFDP) - Robert Wood Johnson Foundation

Additional Details

RFP Snapshot: The Harold Amos Medical Faculty Development Program (AMFDP) offers four-year postdoctoral research awards to faculty from historically marginalized backgrounds who can achieve senior rank in academic medicine, dentistry, or nursing. This program supports the development of faculty to enhance their influence as leaders, researchers, and advisors in supporting a Culture of Health, in which everyone has the chance to live the healthiest life possible.

Max Amount and Period: $420,000 over 4 years

Eligibility: Applicants must be from historically marginalized backgrounds and be able to describe how their background, identity, or lived experiences have positioned them to contribute to the goals of the program. Examples of marginalized backgrounds include, but are not limited to, first-generation college graduates; individuals from lower socioeconomic backgrounds; individuals from communities of color; and individuals with disabilities. All applications should be US citizens, permanent residents, or be individuals granted DACA status at the time of application. Applicants must be completing or have completed their formal clinical training and must be able to spend at least 70 percent of their time engaged in research.

Due Date: March 19, 2024 at 2PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 21: AACR-Ocular Melanoma Foundation Career Development Award, In Honor of Robert C. Allen, M.D.

Additional Details

RFP Snapshot: The AACR-Ocular Melanoma Foundation Career Development Award, in honor of Robert C. Allen, MD represents a joint effort to encourage and support early-stage investigators to conduct ocular/uveal melanoma research and establish a successful career path in ophthalmology, ocular oncology, uveal melanoma biology, or a similar field. Research must have direct applicability and relevance to ocular/uveal melanoma and must be translational or clinical in nature.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must have a doctoral degree in a related field and not be a candidate for a further doctoral degree. At the start of the grant term, applicants must hold a faculty position at the rank of Instructor, Assistant Professor, Research Assistant Professor, or equivalent and have completed their most recent doctoral degree within the past 11 years. Applicants must also have independent laboratory space. Applicants must be AACR members in good standing. Nonmembers can apply for membership online.

Due Date: March 21, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 22: Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) - NIH/NCI

Additional Details

RFP Snapshot: This funding opportunity is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, and/or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies.

Max Amount and Period: $850,000 over 5 years

Eligibility: Individuals from U.S. and LMIC institutions are eligible PDs/PIs. At least one individual from a proposed LMIC institution must serve as a PD/PI or other key personnel. Individuals from non-U.S. high income country institutions are not eligible as PDs/PIs, but may participate as partners or collaborators in proposed programs. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

Due Date: March 22, 2024 at 5PM CST

March 22: COG Hematopoietic Malignancies Integrated Translational Science Center - Children's Oncology Group

Additional Details

RFP Snapshot: The Hematopoietic Malignancies Integrated Translational Science Center is meant to foster the development and implementation of translational research studies that will support future clinical trials in hematopoietic malignancies. This mechanism is to support projects with pre-existing data from primary patient samples.

Max Amount and Period: $150,000  for 1 year

Eligibility: COG members are invited to apply. Non-members at COG institutions are also invited to apply, but must become a COG Full individual if awarded.

Due Date: March 22, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 25: 2024 Reach Grant - Alex's Lemonade Stand Foundation

Additional Details

RFP Snapshot: The Reach Grant seeks to remove one of the barriers to translation of innovative ideas by providing support for important pre-clinical hypothesis-driven research projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support translational studies that will result in a phase 1 and/or 2 clinical trial, two to three years from the project end date. Examples of appropriate research projects include but aren’t limited to, completing IND-enabling studies, providing requisite pre-clinical data for clinical trial development, or perhaps through the validation of biomarkers that will enable selection of the correct patients for entry into new clinical trials. Proposals must be focused on childhood cancers (<19 years of age) and be focus on late-translational potential. Each proposal must include a plan to bring the project to a clinical trial.

Max Amount and Period: $250,000 over 2 years

Eligibility: Applicants must have an MD, PhD, or MD/PhD and have demonstrated a track record of pediatric cancer research experience with translational research. Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged. Applicants need not be US citizens.

Due Date: March 25, 2024 at 7PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 27: LOI: OCRA Health Equity Research Grant - Ovarian Cancer Research Alliance

Additional Details

RFP Snapshot: The objective of this grantmaking program is to support research projects that promote equity, inclusivity, and evidence-based approaches to overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related gynecologic cancers. For the purposes of this grant, marginalized communities are defined as groups that have historically struggled with equal access to care due to gender identity, sexual orientation, race, ethnicity, disability status, and language barriers. The primary review criteria will be the likelihood that the investigators can leverage this funding to explore ideas specifically related to reducing health disparities, with long-term impact for the field.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants at all stages of their careers are eligible. Applicants must have their PhD, ScD, MD, or other doctoral degree at the time of application. International applicants are welcome to apply.

Due Date: Letter of Intent Due: March 27, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 27: LOI: OCRA Collaborative Research Development Grant - Ovarian Cancer Research Alliance

Additional Details

RFP Snapshot: The purpose of this grantmaking program is to provide funds for ovarian cancer and/or related gynecologic cancers research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged. The primary review criteria will be the likelihood that the investigators can leverage this funding to explore ideas specifically related to reducing health disparities, with long-term impact for the field.

Max Amount and Period: $900,000 over 3 years

Eligibility: Applicant must have a full-time faculty appointment. At least one key investigator must be a physician with expertise in ovarian cancer. International collaborations are welcome.

Due Date: Letter of Intent Due: March 27, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 27: LOI: OCRA Collaborative Research Development Grant – Microsoft AI for Health - Ovarian Cancer Research Alliance

Additional Details

RFP Snapshot: The purpose of this grantmaking program is to provide funds for ovarian cancer and/or related gynecologic cancers research projects using AI or machine learning that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged. Investigators funded through this grant opportunity have access to support from Microsoft in the form of Azure computing credits, and in-kind data science support. This in-kind support from Microsoft will be in addition to the financial support from OCRA. The primary review criteria will be the likelihood that the investigators can leverage this funding to explore ideas specifically related to reducing health disparities, with long-term impact for the field.

Max Amount and Period: $100,000 over 1-2 years

Eligibility: Applicant must have a full-time faculty appointment. At least one key investigator must be a physician with expertise in ovarian cancer. International collaborations are welcome.

Due Date: Letter of Intent Due: March 27, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 27: LOI: OCRA Mentored Investigator Grant - Ovarian Cancer Research Alliance

Additional Details

RFP Snapshot: This grant (formerly called the Ann Schreiber Mentored Investigator Award) provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research, or relevant area.

Max Amount and Period: $100,000 over 1-2 years

Eligibility: Applicants must be either clinical fellows or post-doctoral fellows with protected time to do the work. Applicants must have a MD/DO and/or PhD. Applicants should be involved in either laboratory, clinical, epidemiologic, or health services research and have a mentor. PhD applicants must be no than 5 years out of their terminal degree at time of application (e.g. terminal degree must have been awarded during 2019 or later); MD/DOs and MD/PhDs must be currently enrolled in a fellowship program. At least 80% of effort should be devoted to research during the tenure of the grant. International applicants are welcome to apply.

Due Date: Letter of Intent Due: March 27, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 27: LOI: OCRA Early Career Investigator Grant - Ovarian Cancer Research Alliance

Additional Details

RFP Snapshot: The Early Career Investigator Grant (ECIG) (formerly called the Liz Tilberis Early Career Award) is for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.

Max Amount and Period: $450,000 over 3 years

Eligibility: Applicants should have strong training in preparation for an investigative career in ovarian cancer research and prior academic accomplishments. Candidates must have an MD/DO and/or PhD degree and should be in the first seven years of their first academic appointment after having completed their fellowship or post-doctoral training (Assistant Professor or equivalent). Individuals who will begin such a position by July 2024 are eligible for this grant. For MDs/DOs or MD/DO-PhDs with clinical responsibilities, at least 50% of the time must be dedicated to ovarian cancer research. For applicants without clinical responsibilities, at least 75% of the time must be dedicated to ovarian cancer research. Early Career Investigator Grants will not be granted to individuals who hold or have had similar early career investigator awards from other funding agencies or foundations. International applicants are welcome to apply.

Due Date: Letter of Intent Due: March 27, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 28: MRA Advancing Drug Discovery to Identify New Therapies: Melanoma Research Alliance

Additional Details

RFP Snapshot: The Advancing Drug Discovery to Identify New Therapies RFA is meant to provide initial support to identify new therapeutic modalities including small molecules, antibodies and cell therapies against validated melanoma targets, with an emphasis on targets that are applicable to rare melanoma subtypes.

Max Amount and Period: $250,000 over 1-2 years

Eligibility: Applicants must hold a full-time faculty appointment at the level of Assistant Professor or above. An investigator may serve as PI on only one proposal submitted to the Next Steps RFA call in any given calendar year. Researchers who have not received prior MRA awards but who have projects that fit within the scope of this RFA are eligible to apply.

Due Date: Letter of Intent Due: March 28, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

March 31: Center for Drug Discovery QuikSTART Grant - WUSTL CDD and Siteman Cancer Center

Additional Details

RFP Snapshot: This award is designed to advance the translation of new discoveries in cancer disease biology into small molecule therapeutics for the benefit of patients. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in-vivo pharmacokinetics, furnishing drug-like molecules for proof-of-concept in vivo pharmacology studies and intellectual property (patent) filing. The QuikSTART award is viewed as a “hand-up” to generate preliminary data to enable successful following-on funding (e.g., NCI, NIH, private foundation, commercial partnership), publication, and patent filing.

Max Amount and Period: $15,000 for 1 year

Eligibility: The PI must have a full-time faculty appointment at Washington University (WU) at the rank of Assistant Professor or above and hold Siteman Cancer Center membership.

Due Date: March 31, 2024 at 5pm CST

March 31: Research Supplements to Promote Diversity in Health-Related Research - NIH/NCI

Additional Details

RFP Snapshot: Supplement project must be relevant to the parent grant project, and the parent grant must have at least two years of NCI support remaining. P30 cannot be used as the parent grant. An R01 is allowed to support a maximum of two (2) Diversity Supplement candidates. An R21 is allowed to support a maximum of one (1) candidate whose career level is graduate student or more junior.

Max Amount and Period: Varies based on career level

Eligibility: See additional details link.

Due Date: March 31, 2024 at 5pm CST

April Deadlines

April 1: ACS Discovery Boost Grant (DBG) - American Cancer Society

Additional Details

RFP Snapshot: Discovery Boost Grants (DBG) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research methodologies, establishing feasibility, or leading pilot tests. It is expected that preliminary data generated from a completed DBG will have the potential to secure additional grant funding to further the research and open new and highly innovative areas for investigation.

Max Amount and Period: $270,000 over 2 years

Eligibility: PIs must have an independent faculty appointment at a US academic institution.

Due Date: April 1, 2024 at 10:59PM CST

Virtual Webinar (90 min): February 28, 2024 at 1PM CST – Register today for webinar on grantsmanship and current ACS funding opportunities. Link to register: https://us06web.zoom.us/meeting/register/tZArd-qprjMqGNwfHoN7a6NK1dYUNvf2DgLP#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 1: ACS Clinician Scientist Development Grant (CSDG) - American Cancer Society

Additional Details

RFP Snapshot: The Clinician Scientist Development Grant (CSDG) supports full-time faculty members in becoming independent investigators as clinician scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.

Special Focus Opportunities: The ACS is offering two areas of special focus for the CSDG this year, including one focused on Radiation Oncology (with ASTRO) and one to support mind-body-spirit wellness in cancer survivors (HEALED).

Max Amount and Period: $405,000 to $675,000 over 3-5 years

Eligibility: Applicants must have a doctoral degree, an active clinical license, and participate in clinical care. They must not be a current or former PI of an individual mentored training grant. They also must not have had an R-level or equivalent grant as PI.

Due Date: April 1, 2024 at 10:59PM CST

Virtual Webinar (90 min): February 28, 2024 at 1PM CST – Register today for webinar on grantsmanship and current ACS funding opportunities. Link to register: https://us06web.zoom.us/meeting/register/tZArd-qprjMqGNwfHoN7a6NK1dYUNvf2DgLP#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 1: ACS Mission Boost, Stage 1 (MBG) - American Cancer Society

Additional Details

RFP Snapshot: STAGE 1 requires the investigator to develop outcome-specific, unequivocal milestones that reduce the risks of studying a new drug, device, or procedure in patients.

Mission Boost Grants (MBG) are designed to support select current and past ACS grantees specifically for the translation of their research to human testing. MBGs are opportunities for American Cancer Society (ACS) grantees to seek additional, or “boost,” resources for innovative, high-risk/high-reward projects.

Max Amount and Period: $270,000 over 2 years

Eligibility: PIs must have an independent faculty appointment at a US academic institution and have held or currently hold one of the following ACS grants for a minimum 1 year:

• Research Scholar Grant (RSG)
• Clinician Scientist Development Grant (CSDG)
• Mentored Research Scholar Grant (MRSG)
• Cancer Control Career Development Award (CCCDA)
• Pilot and Exploratory Projects in Palliative Care (PEP) Award
• ACS Postdoctoral Fellowship (previous fellows only)

Due Date: April 1, 2024 at 10:59PM CST

Virtual Webinar (90 min): February 28, 2024 at 1PM CST – Register today for webinar on grantsmanship and current ACS funding opportunities. Link to register: https://us06web.zoom.us/meeting/register/tZArd-qprjMqGNwfHoN7a6NK1dYUNvf2DgLP#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 1: ACS Mission Boost, Stage 2 (MBG) - American Cancer Society

Additional Details

RFP Snapshot: STAGE 2 supports testing in cancer patients.

Mission Boost Grants (MBG) are designed to support select current and past ACS grantees specifically for the translation of their research to human testing. MBGs are opportunities for American Cancer Society (ACS) grantees to seek additional, or “boost,” resources for innovative, high-risk/high-reward projects.

Max Amount and Period: $545,000 over 18 months

Eligibility: PIs must have an independent faculty appointment at a US academic institution and have held or currently hold a Stage 1 Mission Boost Grant for a minimum of 18 months AND have completed Stage 1 milestones.

Due Date: April 1, 2024 at 10:59PM CST

Virtual Webinar (90 min): February 28, 2024 at 1PM CST – Register today for webinar on grantsmanship and current ACS funding opportunities. Link to register: https://us06web.zoom.us/meeting/register/tZArd-qprjMqGNwfHoN7a6NK1dYUNvf2DgLP#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 1: ACS Research Scholar Grants (RSG) - American Cancer Society

Additional Details

RFP Snapshot: Research Scholar Grants (RSG) provide support for independent, self-directed researchers and clinician scientists, who are investigators licensed to provide patient care and trained to conduct research. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area.

Special Focus Opportunities: The ACS is offering two areas of special focus for the RSG this year, including one focused on Radiation Oncology (with ASTRO) and one to support mind-body-spirit wellness in cancer survivors (HEALED).

Max Amount and Period: $860,000 over 4 years

Eligibility: PIs must work at a US academic institution and have been appointed as an independent, full-time faculty LESS than 10 years ago. Additionally, they may not be the PI on more than one R01 or equivalent grant at the time of application.

Due Date: April 1, 2024 at 10:59PM CST

Virtual Webinar (90 min): February 28, 2024 at 1PM CST – Register today for webinar on grantsmanship and current ACS funding opportunities. Link to register: https://us06web.zoom.us/meeting/register/tZArd-qprjMqGNwfHoN7a6NK1dYUNvf2DgLP#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 8: LOI: HESI THRIVE Grant Program - Health and Environmental Sciences Institute (HESI)

Additional Details

RFP Snapshot: The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

Max Amount and Period: $20,000 to $50,000 over 2 years

Eligibility: Principal investigator(s) must hold an M.D., Ph.D., D.V.M., or equivalent degree. Candidates for these degrees along with their Principal Investigator may apply. All candidates must have an accredited faculty, medical institution, or other research institute appointment and have the ability to conduct independent research with publications in established peer-reviewed medical and scientific journals. This funding opportunity is open internationally. Awardees must be willing to participate in the annual HESI THRIVE research forum – an opportunity to share results and build a network of experts.

Due Date: Letter of Intent Due: April 8, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 8: LOI: PCF Challenge Awards for Metastatic, Lethal Prostate Cancer - Prostate Cancer Foundation

Additional Details

RFP Snapshot: This RFA is for team science applications focused on the investigation of metastatic, lethal prostate cancer. PCF especially encourages applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. PCF also seeks applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.

Max Amount and Period: $1M over 2 years

Eligibility: The team must be composted of at least three investigators from non-profit academic research centers, including one young investigator. The team may be assembled from one institution, or several. The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six- years following completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program. Applicants who are under-represented in biomedical research are highly encouraged to apply.

Due Date: Letter of Intent Due: April 8, 2024 at 2PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 11: AACR-KidneyCan Kidney Cancer Innovation and Discovery Grants - American Association for Cancer Research

Additional Details

RFP Snapshot: The inaugural AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants is a new grant mechanism that seeks to stimulate creative approaches to translate basic research into new treatment options for kidney cancer. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to kidney cancer research. These grants will support basic, translational, and/or clinical research projects that examine important and druggable novel targets and/or biomarkers that are relevant for kidney cancer.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicants must have a PhD, MD, MD/PhD, or equivalent and be an independent investigator affiliated with an academic, medical, or non-profit research institution. No citizenship requirements. Must be AACR Active members in good standing.

Due Date: April 11, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 12: AACR-Lobular Breast Cancer Alliance-Deborah Mueller Foundation Fund Invasive Lobular Carcinoma Innovation and Discovery Grants - American Association for Cancer Research

Additional Details

RFP Snapshot: The AACR-Lobular Breast Cancer Alliance-Deborah Mueller Foundation Fund Invasive Lobular Carcinoma Innovation and Discovery Grants is a new grant mechanism intended to stimulate and develop creative, paradigm-shifting ideas in invasive lobular carcinoma (ILC) to encourage translation into new treatment options that may not be funded through conventional channels. The grants are named for and in honor of Dr. Deborah Mueller, a devoted board member of the LBCA who died precipitously of metastatic ILC. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research. Applications in any aspect of clinical or basic research directly related to lobular breast cancer will be considered. Research proposals should focus on the biology, diagnosis, treatment and/or prevention of lobular breast cancer or its metastases.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicants must have a PhD, MD, MD/PhD, or equivalent and be an independent investigator affiliated with an academic, medical, or non-profit research institution. No citizenship requirements. Must be AACR Active members in good standing.

Due Date: April 12, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 15: 2024 PCF Young Investigator Awards - Prostate Cancer Foundation

Additional Details

RFP Snapshot: PCF seeks applications from the global biomedical research community. Applicants traditionally under-represented in science and medicine are highly encouraged. We seek applications from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of potentially lethal prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired. PCF especially encourages young investigators working on prostate cancer health disparities to apply.

Max Amount and Period: $225,000 over 3 years

Eligibility: Applicants must be within 6 years following completion of degree and most hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent. At least one mentor must be involved. Applicant should not hold grant commitments exceeding $1,000,000 in direct research funding from all sources including institutional funds at the time of application.

Due Date: April 15, 2024 at 2PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 15: Genentech Health Equity Innovation Fund - Genentech

Additional Details

RFP Snapshot: The Genentech Health Equity Innovation Fund catalyzes powerful partnerships – often between health systems and communities – that have the potential to shift policies, mindsets, evidence base, and practices to eliminate inequities in patient health outcomes. Through transformational, multi-year funding, Innovation Fund grantees are pursuing community-driven solutions that have the power to promote lasting, widespread improvements in healthcare but have been historically under-resourced. Genentech is specifically seeking proposals that address inequities in patient outcomes and healthcare workforce experiences across several therapeutic areas, including breast, lung, and liver cancers.

Max Amount and Period: $750,000 over 3 years

Eligibility: Projects must be led by teams that are representative of the patients and communities (e.g. race, ethnicity, gender, sexual orientation) impacted by the proposal. The proposal should aim to tackle institutional or systemic barriers to health equity for patients, students and communities of color, with a focus on addressing racism as a root cause.

Due Date: April 15, 2024 at 11:59PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 18: GFCR Tradiation Grant Program - Gateway for Cancer Research

Additional Details

RFP Snapshot: Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. We strive to fund treatment-based studies at the bedside, including all types of cancers. At Gateway, it is always and only about the patient. Involvement of patient advocates and patient advocacy groups in the design of the clinical trial, incorporating patient-reported outcomes and quality of life tools, and including patient advocates on research study review committees, are all ways to incorporate the patient’s unique perspective into the research study.

Max Amount and Period: $200,000-$1.5M over 2-5 years

Eligibility: Other available programs include:
• NCI/SPORE/P20 Program
• Integrative Research
• Society for Integrative Oncology (SIO)
• Decentralized Clinical Trial Initiative (DCTI)

Due Date: April 18, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 25: LOI: PROTEUS Consortium (Patient-Reported Outcomes Tools: Engaging Users and Stakeholders) - Pfizer

Additional Details

RFP Snapshot: Proposed projects should examine both the resources required and monetary and non-monetary returns on the investment in PROMs programs. This grant is meant to support studies investigating the value of using patient-reported outcome measures (PROMs) in oncology clinical practice for individual patient care. Projects should investigate the use of PROMs in adult cancer patients. Proposals must include patients with breast cancer and/or prostate cancer and/or hematologic malignancies; however, applications do not have to focus solely on those disease areas. For example, proposals that include breast cancer along with other solid tumors are considered within scope.

Max Amount and Period: $100,000 for 1 year

Eligibility: The applicant must have the expertise and data access necessary to conduct the proposed project successfully. In general, the applicant PI will be expected to have a medical or postdoctoral degree (MD, PhD, or equivalent). Applicants with a Master’s degree in a relevant field and sufficient experience will be considered. A multidisciplinary team is encouraged, and should include both clinical and methodologic expertise aligned with the proposal objectives, as well as patient partners.

Due Date: Letter of Intent Due: April 25, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

April 30: Elsa U. Pardee Foundation Grants

Additional Details

RFP Snapshot: This grant is meant to support investigators in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Max Amount and Period: No Limit for 1 year (budget must be reasonably supported by scope of project)

Eligibility: Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.

Due Date: April 30, 2024 at 5PM CST

Application Assistance: Washington University faculty may reach out to Danny Jaschek in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May Deadlines

May 1: FPMR Cancer Rehabilitation Research Grant - Foundation for Physical Medicine and Rehabilitation

Additional Details

RFP Snapshot: This award is to support research on a topic related to physiatric rehabilitation for individuals with cancer-related disability. Special consideration will be given to applications focused on outcomes and/or comparative effectiveness research.

Max Amount and Period: $10,000 for 1 year

Eligibility: The applicant and/or at least one co-investigator must be a member of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) or the Association of Academic Physiatrists (AAP).

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 1: LOI: PhRMA Faculty Starter Grant in Drug Discovery - The PhRMA Foundation

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Drug Discovery offers financial support to individuals beginning independent careers in drug discovery research at the faculty level at an accredited U.S. university. Applicants must be within the first three years of their independent status. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 1: LOI: PhRMA Faculty Starter Grant in Drug Delivery - The PhRMA Foundation

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Drug Delivery offers financial support to individuals beginning independent careers at the faculty level at an accredited U.S. university in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. Applicants must be within the first three years of their independent status.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 1: LOI: PhRMA Faculty Starter Grant in Translational Medicine - The PhRMA Foundation

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Translational Medicine offers financial support to individuals beginning independent research careers at the faculty level at an accredited U.S. university. Applicants must be within the first three years of their independent status. The PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 12: Robert A. Winn Diversity in Clinical Trials Career Development Award - AACR / Bristol Myers Squibb Foundation / Gilead Sciences, Inc. / VCU

Additional Details

RFP Snapshot: This award is designed to support the career development of early-stage investigator physicians who are underrepresented in medicine, and physicians who have demonstrated a commitment to increasing diversity in clinical research.

Max Amount and Period: $240,000 over 2 years

Eligibility: Eligible applicants must identify with one or more of the following racial/ethnic groups: African American or Black, Hispanic or Latinx, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or Southeast Asian OR must have demonstrated a commitment to increasing diverse patient participation in clinical trials. Applicants must be US citizens or Lawful Permanent Residents. Applicants must hold the degree of MD, MD/PhD, DO, or DO/PhD and have completed their terminal degrees within the past 10 years. They must also not have any substantial NIH research grants.

Due Date: May 12, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 15: Freeman Hrabowski Scholars Program - Howard Hughes Medical Institute

Additional Details

RFP Snapshot: Freeman Hrabowski Scholars will be outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion through their mentoring efforts and understanding of systemic exclusion and marginalization in science of trainees from different backgrounds. Scholars will prioritize scientific excellence in their own research while creating an inclusive lab climate that serves as a model within their own institutions and beyond. Eligible research areas are in the biological and biomedical sciences and include many scientific disciplines in a wide range of organisms.

Max Amount and Period: $8.6M over 10 years (full salary and benefits – $400,000/year for first 5 years and $600,000/year for second 5 years)

Eligibility: Applicants must hold a PhD and/or MD (or equivalent). They must have begun their first post-training position and tenure-track (or equivalent) faculty position on or after 3/1/2020, or have accepted an offer for a tenure-track (or equivalent) position that will begin no later than 3/1/2025. Applications are encouraged from individuals of all backgrounds, including members of groups underrepresented in science and from institutions not previously affiliated with HHMI.

Due Date: May 15, 2024 at 2PM CST

Virtual Webinar (60 min): March 4, 2024 at 1PM CST – Register today to learn more about the 2025 competition. Link to register: https://hhmi.zoom.us/webinar/register/WN_SO-DMM2XQymG1tibQFreyQ

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

May 15: Notice of Special Interest (NOSI): Administrative Supplements for NCI Global Oncology Mentored Research - NIH/NCI

Additional Details

RFP Snapshot: This NOSI encourages eligible grantees to apply for administrative supplements to support cancer research career development of early-stage Low- and Middle-Income Country (LMIC) investigators (ESLIs). The NCI Global Oncology Mentored Research Supplement initiative is designed to support high-quality mentored research experiences for ESLIs within the context of NCI extramural research projects. The overarching goal of this supplement is to strengthen the capacity of LMIC investigators to conduct high-quality independent and/or collaborative research in their home institutions thereby generating context-appropriate evidence to address the growing cancer problem in LMICs.

Max Amount and Period: $125,000 for 1 year

Eligibility: Eligible Parent Awards: R01, R35, R37, P01, P20, P50, U01, U19, U54, UH2, UH3, UG1, UG3 or UM1

Due Date: June 5, 2024 at 5PM CST

June Deadlines

June 5: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: No limit over 5 years, but must reflect needs of project

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

June 5: Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: $275,000 over 2 years

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

June 5: Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: $100,000 over 2 years

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

June 5: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) - NIH/NCI

Additional Details

RFP Snapshot: This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.

Max Amount and Period: No limit over 5 years, but must reflect needs of project

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

June 30: Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials - NIH/NCI

Additional Details

RFP Snapshot: This NOSI is to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials – by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.

Max Amount and Period: $125,000 for 1 year (cannot exceed the costs of the current parent award)

Eligibility: Eligible Parent Awards: R01, UG1, U01, U24, and U54. Parent award must be active, and cannot be in a no-cost extension.

Due Date: June 30, 2024 at 5PM CST